This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n9http://localhost/temp/predkladatel/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n10http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61988987%3A17110%2F14%3AA1501CGB%21RIV15-MSM-17110___/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61988987%3A17110%2F14%3AA1501CGB%21RIV15-MSM-17110___
rdf:type
n11:Vysledek skos:Concept
dcterms:description
In the MM-015 trial, melphalan - prednisone - lenalidomide followed by lenalidomide maintenance (MPR-R) signifcantly prolonged progression-free survival versus melphalan - prednisone (MP) in newly diagnosed patients with multiple myeloma aged >= 65 years. Health-related quality of life (HRQoL), a secondary endpoint of MM-015, was also improved with MPR-R. This sub-analysis evaluated the impact of individual predictive factors on HRQoL. Patients completed HRQoL questionnaires at baseline, every third cycle and at progressive disease (PD)/treatment discontinuation. In the MM-015 trial, melphalan - prednisone - lenalidomide followed by lenalidomide maintenance (MPR-R) signifcantly prolonged progression-free survival versus melphalan - prednisone (MP) in newly diagnosed patients with multiple myeloma aged >= 65 years. Health-related quality of life (HRQoL), a secondary endpoint of MM-015, was also improved with MPR-R. This sub-analysis evaluated the impact of individual predictive factors on HRQoL. Patients completed HRQoL questionnaires at baseline, every third cycle and at progressive disease (PD)/treatment discontinuation.
dcterms:title
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
skos:prefLabel
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
skos:notation
RIV/61988987:17110/14:A1501CGB!RIV15-MSM-17110___
n3:aktivita
n4:I
n3:aktivity
I
n3:cisloPeriodika
7
n3:dodaniDat
n8:2015
n3:domaciTvurceVysledku
n13:9622748
n3:druhVysledku
n17:J
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n10:predkladatel
n3:idSjednocenehoVysledku
16365
n3:idVysledku
RIV/61988987:17110/14:A1501CGB
n3:jazykVysledku
n7:eng
n3:klicovaSlova
Health-related quality of life (HRQoL); lenalidomide; multiple myeloma; minimal important difference (MID); QLQ-C30; QLQ-MY20
n3:klicoveSlovo
n6:Health-related%20quality%20of%20life%20%28HRQoL%29 n6:QLQ-C30 n6:QLQ-MY20 n6:multiple%20myeloma n6:lenalidomide n6:minimal%20important%20difference%20%28MID%29
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[0D863C74AA14]
n3:nazevZdroje
Leukemia & Lymphoma
n3:obor
n16:FE
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
10
n3:rokUplatneniVysledku
n8:2014
n3:svazekPeriodika
55
n3:tvurceVysledku
Lewis, Philip Delforge, Michel Dimopoulos, Meletios A. Zhang, Jingshan Hájek, Roman Mei, Jay Millar, Stefanie Palumbo, Antonio Kropff, Martin Petrucci, Maria Teresa
s:issn
1042-8194
s:numberOfPages
9
n9:organizacniJednotka
17110